<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In six index cases/families referred for <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) molecular diagnosis, we identified six novel mutations in the FBN1 gene: c.1753G&gt;C (p.Gly585Arg), c.2456G&gt;A (p.Gly819Glu), c.4981G&gt;A (p.Gly1661Arg), c.5339G&gt;A (p.Gly1780Glu), c.6418G&gt;A (p.Gly2140Arg) and c.6419G&gt;A (p.Gly2140Glu) </plain></SENT>
<SENT sid="1" pm="."><plain>These variants, predicted to result in Glycine substitutions are located at the third position of a 4 amino acids loop-region of calcium-binding Epidermal Growth Factor-like (cb-EGF) fibrillin-1 domains 5, 9, 24, 25 and 32 </plain></SENT>
<SENT sid="2" pm="."><plain>Familial segregation studies showing cosegregation with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> manifestations or de novo <z:hpo ids='HP_0000005'>inheritance</z:hpo> in addition to in silico analyses (conservation, 3D modeling) suggest evidence for a crucial role of the respective Glycine positions </plain></SENT>
<SENT sid="3" pm="."><plain>Extending these analyses to <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="29947">Glycine residue</z:chebi> at position 3 of this 4 residues loop in fibrillin-1 cb-EGF with the UMD predictor tool and alignment of 2038 available related sequences strongly support a steric strain that only allows Glycine or even <z:chebi fb="0" ids="32441">Alanine residues</z:chebi> for domain structure maintenance and for the fibrillin functions </plain></SENT>
<SENT sid="4" pm="."><plain>Our data compared with those of the literature strongly suggest the existence of a cb-EGF domain subtype with implications for related diseases </plain></SENT>
</text></document>